Side-by-side · Research reference
KPVvsMGF
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongAUTO-DRAFTED13/39 cited
BAnimal-StrongHUMAN-REVIEWED14/55 cited
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
MGF
IGF-1Ec Splice Variant · Muscle-Specific
SQ · Research context only
01Mechanism of Action
Parameter
KPV
MGF
Primary target
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Satellite cells (Pax7+) in skeletal muscleMoore 2018
Pathway
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Mechanical stress → IGF-1Ec mRNA upregulation → Local E-domain peptide release → Satellite cell activation
Downstream effect
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Satellite cell proliferation, myoblast differentiation, muscle fiber repair
Feedback intact?
No melanocortin receptor binding
—
Origin
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Alternative splicing of IGF-1 gene (exons 4-6) produces IGF-1Ec precursor; E-domain cleaved post-translationallyArmakolas 2016Vassilakos 2017
Antibody development
—
—
02Dosage Protocols
Parameter
KPV
MGF
Frequency
Daily or 2–3× per week
—
Lower / starter dose
100 mcg / day
—
Evidence basis
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Animal models + in vitro only
Duration
4–8 weeks per cycle
—
Reconstitution
Bacteriostatic water (SQ form)
—
Timing
No specific time; often taken with / before meals (oral)
—
Half-life
Hours (estimated; rapid tissue uptake)
—
Synthetic peptide
—
24-amino-acid E-domain sequence
Corresponds to human IGF-1Ec exons 4-6 region.
Rodent cardiac model
—
200 μg/kg via peptide-eluting microstructures
Post-MI injection; improved ejection fraction by 8 weeks.
Acute delivery (mouse MI)
—
Single bolus within 12 hrs post-infarctionShioura 2014
Delayed decompensation; no human protocol established.
Human evidence
—
None — no published clinical trials
All dosing extrapolated from animal models.
Detection in doping
—
Full-length MGF detected via LC-MS in illicit productsThevis 2014
WADA-prohibited since 2005; no therapeutic indication.
04Side Effects & Safety
Parameter
KPV
MGF
Injection site reaction
Mild irritation
—
GI symptoms
Rare nausea (oral form)
—
Long-term safety
Limited human data
—
Pregnancy / OB
Avoid — insufficient data
—
Human safety data
—
None — no clinical trials published
Theoretical IGF-1 axis risk
—
Chronic IGF-1Ec overexpression linked to cancer progression (prostate, colorectal, breast)
Tumor promotion
—
IGF-1Ec overexpressed in osteosarcoma, colorectal polyps with dysplasia, endometrial cancer
Antibody development
—
Unknown — no longitudinal human exposure data
Local injection reaction
—
Presumed similar to other peptides (erythema, induration) — no direct evidence
Dysregulated expression with age
—
Older adults (70+ yrs) show blunted IGF-1Ec response post-exercise vs youngMoore 2018
Absolute Contraindications
KPV
- ·Pregnancy / breastfeeding
MGF
- ·Active malignancy or history of IGF-1-sensitive cancers (prostate, colorectal, breast, osteosarcoma)
- ·No established therapeutic use — investigational only
Relative Contraindications
KPV
- ·Active autoimmune disease (theoretical)
MGF
- ·Family history of IGF-1-axis malignancies
- ·Use outside research setting
05Administration Protocol
Parameter
KPV
MGF
1. Reconstitution
Add 1 mL bacteriostatic water to vial per labelling.
MGF (E-domain peptide) has no approved clinical protocol. All published data derive from animal models or in vitro experiments.
2. Form
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
Commercially available MGF corresponds to the 24-amino-acid human E-domain (hEc). Rodent E-domain (Eb) is structurally distinct and not interchangeable.
3. Timing
Morning preferred; oral form taken with / before meals.
Rodent studies used peptide-eluting polymeric microstructures (cardiac) or direct intramuscular injection. Routes and doses non-translatable to humans.Peña 2015Shioura 2014
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
MGF peptides prohibited in sport since 2005. Detection via LC-MS established for full-length MGF products.Thevis 2014
5. Needle
29–31G insulin syringe (SQ form).
Any human use falls outside approved medical practice and regulatory frameworks. No safety or efficacy data exist.
06Stack Synergy
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions
MGF
+ BPC-157
Multi-pathwayMGF activates satellite cells for muscle fiber repair; BPC-157 promotes angiogenesis, collagen synthesis, and tendon healing via distinct pathways (VEGF, FAK, integrin signaling). Theoretical synergy in post-injury contexts combines myogenic (MGF) and stromal (BPC-157) repair mechanisms. Both lack human validation.
- MGF
- No established dose
- BPC-157
- 250–500 mcg SQ near injury site
- Context
- Animal models only
- Primary benefit
- Theoretical multi-tissue repair (muscle + tendon/ligament)
+ TB-500
ModerateTB-500 (thymosin beta-4 fragment) enhances actin polymerization, cell migration, and angiogenesis—complementary to MGF satellite cell activation. Both upregulated post-injury; combined use presumed additive for muscle regeneration in preclinical models.
- MGF
- No established dose
- TB-500
- 2–5 mg SQ weekly
- Context
- Animal models only
- Primary benefit
- Satellite cell activation + enhanced migration/angiogenesis